Biologic Drug Allergy: Infusion Reactions, Anti-Drug Antibodies & Care

Biologic drugs is the broader category encompassing all therapeutic proteins derived from living cells, including monoclonal antibodies, fusion proteins (etanercept, abatacept), recombinant enzymes (pegaspargase), and cytokines. Monoclonal antibodies are a specific subtype of biologics. TNF inhibitors (infliximab, adalimumab, golimumab, certolizumab), IL-inhibitors (secukinumab, dupilumab, tocilizumab), and fusion proteins (etanercept, abatacept) are all biologics. The monoclonal antibodies page covers drug-specific deep dives on cetuximab, rituximab, and omalizumab with their unique allergy stories. This page covers the class-wide immunogenicity framework and TNF inhibitor landscape that applies to the majority of prescribed biologics.

Infliximab is a chimeric antibody containing approximately 33% murine protein sequences, making it more recognizable as foreign by the human immune system. This drives human anti-chimeric antibody (HACA) formation in 10 to 61% of patients, depending on assay and co-therapy. Adalimumab is fully human (0% mouse protein), generating lower but still significant ADA rates of 5 to 38%. The nomenclature gradient — -ximab (chimeric), -zumab (humanized, ~10% mouse), -umab (fully human) — tracks immunogenicity, though even fully human biologics trigger antibody formation. Concomitant methotrexate reduces ADA rates by approximately 50% across all TNF inhibitor subtypes by suppressing T-cell-dependent B-cell antibody production.

Methotrexate suppresses the T-cell help required for B cells to undergo class switching and produce high-affinity anti-drug antibodies against therapeutic proteins. By dampening this adaptive immune response, low-dose methotrexate — typically 10 to 15 mg weekly — reduces ADA formation by approximately 50% across the TNF inhibitor class, including infliximab, adalimumab, golimumab, and certolizumab. This immunogenicity-prevention benefit is a primary rationale for combination therapy in rheumatoid arthritis, Crohn's disease, and psoriasis, in addition to the additive therapeutic benefit. Patients who cannot tolerate methotrexate may use azathioprine or 6-mercaptopurine as ADA-suppression alternatives, though with less robust evidence than methotrexate.

The BWH 12-step rapid desensitization protocol, developed by Mariana Castells at Brigham and Women's Hospital, uses three bags of the patient's prescribed biologic at progressively higher concentrations — 1/100th, 1/10th, and full strength of the target dose. Starting with a very small dose, the infusion rate is doubled every 15 minutes across 12 steps over approximately 6 hours in total. Premedication includes diphenhydramine, famotidine, acetaminophen, and montelukast. The protocol achieves greater than 95% success across infliximab, rituximab, cetuximab, omalizumab, and trastuzumab desensitizations. It must be repeated for every subsequent treatment cycle, as tolerance is procedure-specific and does not persist between sessions.

Switching between TNF inhibitors is possible but carries increased immunogenicity risk. Patients who develop anti-drug antibodies to one TNF inhibitor have 2 to 3 times higher risk of developing antibodies to another within the same class, because the immune system has already mounted a response to therapeutic protein structures. Switching from a chimeric biologic like infliximab to a fully human one like adalimumab may moderately reduce immunogenicity due to lower foreign protein content. However, if immunogenicity is the primary driver of treatment failure, switching to a biologic targeting a completely different pathway — IL-17 inhibitors, IL-23 inhibitors, IL-6 inhibitors, or JAK inhibitors — avoids cross-immunogenicity entirely, as these agents share no structural epitopes with TNF inhibitors.

Paradoxical psoriasis is not a traditional drug allergy. It is an immunologic phenomenon affecting 2 to 5% of patients on anti-TNF therapy, particularly those treated for rheumatoid arthritis, Crohn's disease, or ankylosing spondylitis who have no prior psoriasis history. The proposed mechanism involves disruption of the TNF-alpha-IFN-gamma balance, leading to plasmacytoid dendritic cell overactivation and excessive type I interferon production that redirects the immune response toward a psoriasiform pattern. It typically presents as new-onset palmoplantar pustular psoriasis or plaque psoriasis, distinct from the patient's original inflammatory condition. Management may include topical treatments, continuing the biologic with topical therapy, or switching to a different mechanism class.

Polyethylene glycol (PEG) is used to modify some biologics, most notably pegaspargase (PEG-asparaginase used in pediatric leukemia treatment) and certolizumab pegol (PEGylated Fab fragment anti-TNF). IgE-mediated PEG allergy has gained attention since PEG is present in mRNA COVID-19 vaccine lipid nanoparticles and colonoscopy preparation solutions. Patients with confirmed PEG allergy have elevated risk of reacting to any PEGylated biologic. Cross-reactivity also exists with polysorbate 80, which is used in docetaxel and some vaccine formulations. Skin testing with stepwise PEG concentrations is recommended before administering any PEGylated biologic to patients with a PEG allergy history, as the systemic reaction rate during testing itself is approximately 25%.

Injection site reactions (ISRs) occur in approximately 20% of patients taking adalimumab or etanercept, making them among the most common adverse events for these subcutaneous biologics. ISRs present as redness, swelling, pain, and itching at the injection site, typically appearing within 30 to 60 minutes of injection and resolving within a few days. They are generally local Type IV delayed reactions or simple irritant responses rather than systemic IgE-mediated allergy. Rotating injection sites, allowing the drug to reach room temperature before injection, and applying cool compresses after injection all help reduce ISR frequency and severity. Persistent or worsening ISRs warrant discussion with your rheumatologist to evaluate technique and site rotation practices.